Clinical trial

Aumolertinib With Chemotherapy or Alone Compared With Osimertinib in Patients With Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer

NCT05493501

Study summary

ClinicalTrials.gov

Aumolertinib With Chemotherapy or Alone Compared With Osimertinib in Patients With Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer

Design: INTERVENTIONAL · Status: TERMINATED · Phase: PHASE3

Loading study purpose, treatment groups and outcomes…

View the complete registry record, eligibility and contacts at ClinicalTrials.gov

Drugs and interventions used in this trial

8 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

DRUG · Unmapped registry intervention Aumolertinib monotherapy Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention Osimertinib monotherapy Find medicine records · Find other trials using this name

DRUG · Mapped RxNorm record Pemetrexed Normalized identity: pemetrexed View linked drug · Find medicine records · Find other trials using this name

DRUG · Mapped RxNorm record Cisplatin Normalized identity: cisplatin View linked drug · Find medicine records · Find other trials using this name

DRUG · Mapped RxNorm record Carboplatin Normalized identity: carboplatin View linked drug · Find medicine records · Find other trials using this name

DRUG · Mapped RxNorm record Paclitaxel Normalized identity: paclitaxel View linked drug · Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention Nab paclitaxel Find medicine records · Find other trials using this name

DRUG · Mapped RxNorm record Gemcitabine Normalized identity: gemcitabine View linked drug · Find medicine records · Find other trials using this name

StatusTERMINATED

Study typeINTERVENTIONAL

Start date2022-12-14

PhasePHASE3

Conditions

NSCLCverified · MONDO: non-small cell lung carcinoma

Interventions

Aumolertinib monotherapyDRUG

Osimertinib monotherapyDRUG

PemetrexedDRUG · verified · RxNorm: pemetrexed

CisplatinDRUG · verified · RxNorm: cisplatin

CarboplatinDRUG · verified · RxNorm: carboplatin

PaclitaxelDRUG · verified · RxNorm: paclitaxel

Nab paclitaxelDRUG

GemcitabineDRUG · verified · RxNorm: gemcitabine

Sponsors & collaborators

EQRx International, Inc.lead sponsor

Mapped research locations

NashvilleTennessee, United States1 TacomaWashington, United States1 HollywoodFlorida, United States1 ChattanoogaTennessee, United States1 Des MoinesIowa, United States1 Pembroke PinesFlorida, United States1 SpringdaleArkansas, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT05493501 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.